Alkermes PLC
ALKSHealthcare|Drug Manufacturers - Specialty & Generic|Ireland
$51.95
-1.82 (-3.39%)
DCF (FCF)
$20.11
Earnings Power
$12.19
Upcoming Data Readouts (8)
Sep 2026
Est. completion
P3Schizophrenia
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
NCT05303064n=220
Nov 2026
Est. completion
P2Idiopathic Hypersomnia
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
NCT06843590n=126
May 2027
Est. completion
P3Narcolepsy Type 1
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383n=150
May 2027
Est. completion
P3Narcolepsy Type 2
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443n=176
Jun 2027
Est. completion
P3Narcolepsy Type 1
A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)
NCT07540897n=150
Jul 2027
Est. completion
Jun 2028
Est. completion
P2P3Narcolepsy Type 1
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
NCT06767683n=256
Dec 2033
Est. completion